Cancer Management and Research最新文献

{"title":"Erianin Suppresses Pancreatic Cancer Progression by Inducing Cell Cycle Arrest and Ferroptosis.","authors":"Xiao Qu, Bin He, Yaohui Zhang, Li Hang, Ping Lu","doi":"10.2147/CMAR.S540437","DOIUrl":"10.2147/CMAR.S540437","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is a highly aggressive malignancy with limited therapeutic options and poor prognosis. Erianin, a natural product, has shown anti-cancer properties in various malignancies, but its effects on pancreatic cancer and the underlying mechanisms remain poorly understood.</p><p><strong>Aim: </strong>This study aimed to evaluate the anti-tumor effects of erianin on pancreatic cancer cells and to explore the regulatory mechanisms involved.</p><p><strong>Methods: </strong>PANC-1 and ASPC-1 pancreatic cancer cells were treated with erianin at different concentrations. Cell viability and proliferation were assessed using the Cell Counting Kit-8 (CCK-8) assay and colony formation assay. Cell cycle distribution was analyzed by flow cytometry. Ferroptosis was evaluated by measuring levels of Fe²⁺, total iron, and lipid reactive oxygen species (ROS). Western blotting was used to detect</mark> the expression of cell cycle regulators and ferroptosis-related proteins.</p><p><strong>Results: </strong>Erianin significantly suppressed pancreatic cancer cell viability and proliferation in a dose-dependent manner. It induced G0/G1 phase arrest, accompanied by downregulation of cyclin D1 and cyclin A. Furthermore, erianin promoted ferroptosis, as evidenced by increased Fe²⁺, total iron, and lipid ROS levels, along with reduced glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) expression. The ferroptosis inhibitor Ferrostatin-1 reversed these effects, validating ferroptosis as a critical mechanism in erianin's anti-cancer activity.</p><p><strong>Conclusion: </strong>Erianin exerts potent anti-tumor effects on pancreatic cancer cells by inducing cell cycle arrest and ferroptosis. These findings establish erianin as a promising therapeutic candidate for pancreatic cancer treatment.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1657-1666"},"PeriodicalIF":2.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on Risk Factors and Treatment Strategies for Deep Vein Thrombosis in Patients with Multiple Myeloma.","authors":"Yifei Guo, Lixiang Yan, Xi Yang, Chenyang Fan, Jianati Reaila, Yanan Jia, Xiaogang Hao, Feng Ju, Zhexin Shi","doi":"10.2147/CMAR.S533589","DOIUrl":"10.2147/CMAR.S533589","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a malignant tumor originating from plasma cells, and in recent years, its incidence has shown a significant upward trend in our country. Venous thromboembolism (VTE) is a relatively common complication in multiple myeloma (MM) patients. Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism (PE), with patients facing a high risk of DVT during treatment. Studies have shown that the procoagulant state of MM, inflammatory response, and the therapeutic drugs used significantly increase the incidence of DVT. However, the exact mechanisms behind the increased risk of venous thrombosis are not yet fully understood. The occurrence of DVT not only has a severely negative impact on patient survival rates but also leads to adjustments in treatment plans and a reduction in patients' quality of life. This article analyzes the relationship between risk factors for DVT and MM, exploring current diagnostic methods, risk assessment tools, and personalized preventive treatment strategies, ultimately proposing future research directions. Through a review and analysis of relevant literature, it aims to enhance the understanding of multiple myeloma and deep vein thrombosis, providing references for clinical diagnosis and treatment.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1667-1677"},"PeriodicalIF":2.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Margin Involvement After Excision with Preoperative Dermoscopic Assessment of Head and Neck Basal Cell Carcinomas - a Retrospective Study.","authors":"Laura Ziuzia-Januszewska, Irena Walecka, Małgorzata Kołos, Damian Zimoń, Marcin Januszewski, Eliza Brożek-Mądry","doi":"10.2147/CMAR.S519809","DOIUrl":"10.2147/CMAR.S519809","url":null,"abstract":"<p><strong>Purpose: </strong>Basal cell carcinoma (BCC) is the most common cancer in Caucasians, and its incidence is rising. Incompletely treated tumors may cause destruction of adjacent structures and significant morbidity. This study aimed to evaluate margin involvement after surgical BCC excision with preoperative dermoscopic assessment and identify tumor features associated with positive and inadequate margins.</p><p><strong>Methods: </strong>We retrospectively analyzed electronic medical records of 230 head and neck BCCs, surgically excised after preoperative dermoscopic border assessment.</p><p><strong>Results: </strong>Overall, 14 cases (6.2%) had positive margins, and 35 (16.1%) had inadequate (positive or close) margins. Lateral margins were positive and inadequate in 8 (3.5%) and 16 (7%) cases, respectively, while deep margins in 11 (4.8%) and 27 (12.6%) cases, respectively. The observed rate of lateral margin positivity is notably low compared to prior reports. Recurrence occurred in 2.8% of cases. Factors associated with inadequate margins included H-zone location (OR=3 [95% CI 1.1-8.1]), particularly on the nose (OR=2.3 [95% CI 1.1-4.8]), aggressive histological subtypes (OR=4.3 [95% CI 1.7-11.1]), ulceration (OR=2.3 [95% CI 1.1-4.8]), inflammatory infiltration (OR=3.9 [95% CI 1.7-8.7]), and elastosis (OR=2.9 [95% CI 1.2-6.8]). Lateral inadequate margin was more frequent in recurrent tumors (OR 5.3 [95% CI 1.6-16.9]).</p><p><strong>Conclusion: </strong>This study supports the role of preoperative dermoscopic lesion borders assessment and multidisciplinary approach in BCC treatments, especially for high-risk tumors when micrographic surgery is not feasible. While further randomized controlled trials are warranted, incorporating preoperative dermoscopic assessment of BCC borders into clinical practice could improve patient outcomes and reduce healthcare costs.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1643-1656"},"PeriodicalIF":2.6,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of R-Loops in Lung Adenocarcinoma: Implications for Immune Response and Drug Sensitivity.","authors":"Jianjun Jiang, Yingxin Zhang, Biying Men, Yujing He, Liang Yun, Fangfang Li, Xuguang Rao, Kaican Cai, Shuan Rao","doi":"10.2147/CMAR.S533571","DOIUrl":"10.2147/CMAR.S533571","url":null,"abstract":"<p><strong>Background: </strong>R-loops, RNA-DNA hybrid structures, play essential roles in maintaining genomic stability and regulating transcription. This study aims to identify key R-loop regulatory genes as prognostic markers for LUAD and explore their associations with immunotherapy response and drug sensitivity, supporting personalized treatment strategies.</p><p><strong>Methods: </strong>We integrated 1771 R-loops genes with differentially expressed genes in LUAD. Through univariate Cox, LASSO, and multivariate Cox analyses, we constructed an R-loops prognostic risk score (R-loops Score) and validated it in three independent GEO cohorts. Correlations with clinical variables, immune features, and drug response were examined. Key genes were further evaluated by qPCR and Western blot in LUAD cell lines and tumor tissues.</p><p><strong>Results: </strong>Patients with high R-loops Scores had significantly poorer overall survival compared with low-score patients. A nomogram combining the R-loops Score and clinical factors achieved AUCs of 0.732, 0.713, and 0.719 for predicting 1-, 2-, and 5-year OS, respectively. Pathway enrichment indicated that high-score tumors were enriched in cell cycle regulation, phase separation, and epithelial-mesenchymal transition. High R-loops Scores were associated with male sex, advanced stages, immune evasion and immunotherapy resistance, but increased chemotherapy and targeted therapy sensitivity. EIF3B was further validated as a key gene through analysis of a local patient cohort.</p><p><strong>Conclusion: </strong>The R-loops Score represents a promising prognostic tool for LUAD, offering valuable insights into survival outcomes, immune characteristics and drug responsiveness. Notably, qPCR and Western blot validation consistently confirmed EIF3B as a key gene, further supporting their potential as biomarkers. These results support future research and serve as a reference for the personalized precision treatment of LUAD.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1625-1642"},"PeriodicalIF":2.6,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Chemotherapy Medication of <i>Evodia lepta</i> (Spreng). Merr. on the Viability of Tongue Cancer Cells Through the PD-L1/MMP14/HSPA5 Pathway.","authors":"Jingkun Chen, Xiaohui Zheng, Xiaobing Wang, Ching-Feng Weng","doi":"10.2147/CMAR.S533380","DOIUrl":"10.2147/CMAR.S533380","url":null,"abstract":"<p><strong>Background: </strong>Oral tongue squamous cell carcinoma (OTSCC), the most prevalent oral malignancy, lacks effective treatments.</p><p><strong>Objective: </strong>Evaluate Evodia lepta (<i>E.</i> <i>lepta</i>) as a potential OTSCC therapeutic.</p><p><strong>Methods: </strong>Cell viability (CCK-8) and protein expression (Western blot) were assessed in OTSCC (CAL27, TCA8113) and 3T3 cells after 24h treatment with <i>E. lepta</i> or cisplatin.</p><p><strong>Results: </strong>Cisplatin significantly reduced the viability in all cells (IC₅₀: 3T3 = 9.5 μM; CAL27/TCA8113 = 3.5 μM). <i>E. lepta</i> selectively targeted OTSCC cells (IC₅₀: CAL27 = 80 μg/mL; TCA8113 = 60 μg/mL) with no 3T3 toxicity. Protein expression analysis revealed that <i>E. lepta</i> downregulated GPX4, ADRM1, MMP14, PD-L1, and HSPA5 in both CAL27 and 3T3 cells. Interestingly, the expression of p17 exhibited divergent regulation between cell types. In contrast, cisplatin treatment upregulated GPX4 and downregulated MMP14, PD-L1, and HSPA5 in CAL27 cells, with p17 regulation opposing that observed with <i>E. lepta</i>.</p><p><strong>Conclusion: </strong><i>E. lepta</i> selectively induces ferroptosis through GPX4 and HSPA5 downregulation, demonstrating multi-target effects including proteostasis disruption (ADRM1), metastasis inhibition (MMP14), and immune evasion suppression (PD-L1). Its GPX4 suppression contrasts with cisplatin's upregulation, suggesting utility in cisplatin-resistant OTSCC. PD-L1 reduction implies immunotherapeutic potential, meriting further study.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1613-1623"},"PeriodicalIF":2.6,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse and Strong TTF-1 Expression Predicts Response to Pemetrexed-Based Immunochemotherapy in Advanced Lung Adenocarcinoma.","authors":"Jun Yamada, Naoe Jimbo, Nanami Yamasaki, Yukihisa Hatakeyama, Tatsunori Kiriu, Natsuhiko Iwamoto, Kanoko Matsumura, Masahiro Katsurada, Keiko Okuno, Kyosuke Nakata, Motoko Tachihara","doi":"10.2147/CMAR.S520436","DOIUrl":"10.2147/CMAR.S520436","url":null,"abstract":"<p><strong>Purpose: </strong>Thyroid transcription factor-1 (TTF-1) is a good prognostic factor for non-small cell lung carcinoma (NSCLC). It is unclear how much TTF-1 staining is sufficient to predict therapeutic response in immunochemotherapy. We evaluated the cut-off of TTF-1 considering the percentage of positive cells and staining intensity as a predictive factor.</p><p><strong>Patients and methods: </strong>We conducted a retrospective multicenter study of patients with advanced lung adenocarcinoma or NSCLC favor adenocarcinoma treated with immunochemotherapy. One pathologist centrally examined the immunohistochemical staining of TTF-1 using 8G7G3/1 and provided scores of 0-5 based on the staining intensity and ratio.</p><p><strong>Results: </strong>We analyzed 95 patients. As TTF-1 has previously been shown to be a predictive factor for pemetrexed, there were significant differences in PFS of patients treated with pemetrexed-based immunochemotherapy between TTF-1 scores of 5 (diffuse and strong staining) and ≤4, but not between 0 (no staining) and 2-4 (partial or weak staining). We defined a TTF-1 score of ≥5 as positive for the predictive factor and the positivity ratio was 61.1%. Patients who tested negative for TTF-1 had a significantly higher proportion of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) <1%. Excluding mutation-positive patients, PFS in TTF-1 positivity was significantly longer than in negativity (8.0 and 5.9, hazard ratio (HR): 0.58 (0.34-0.98), p = 0.04), while TTF-1 negativity was not inferior to positivity in PFS with taxane-based immunochemotherapy. Patients treated with pemetrexed-based immunochemotherapy who tested positive for TTF-1 had significantly longer PFS than those who tested negative (HR: 0.51 (0.27-0.99), p = 0.045) in the multivariate analysis incorporating age, PD-L1, PS, and TTF-1.</p><p><strong>Conclusion: </strong>Diffuse and strong TTF-1 positivity may be useful for the predictive factor for pemetrexed-based immunochemotherapy. TTF-1 staining may be desirable to develop a more optimal immunochemotherapy for lung adenocarcinoma.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1599-1611"},"PeriodicalIF":2.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.","authors":"Zunhao Zhang, Bo Tian, Hui Xu, He Huang, Xianwei Liang, Changwen Bo, Yunfei Bian, Ming Wei, Zhitao Zhao","doi":"10.2147/CMAR.S526924","DOIUrl":"10.2147/CMAR.S526924","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).</p><p><strong>Methods: </strong>A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.</p><p><strong>Results: </strong>Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1-25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38±1.37 at baseline to 2.01±0.35 post-treatment (p<0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).</p><p><strong>Conclusion: </strong>CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1589-1598"},"PeriodicalIF":2.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circ_0061825 Acts as a miR-593-3p Sponge to Promote Breast Cancer Progression by Regulating FGFR3 Expression [Retraction].","authors":"","doi":"10.2147/CMAR.S558488","DOIUrl":"https://doi.org/10.2147/CMAR.S558488","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/CMAR.S269128.].</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1587-1588"},"PeriodicalIF":2.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer.","authors":"Yeasin Ahamed, Lichao Wu, Shantanu Baral, Ashab Uddin Al-Raiyan, Weigui Sun","doi":"10.2147/CMAR.S514439","DOIUrl":"10.2147/CMAR.S514439","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression and influencing factors of serum prostate specific antigen (PSA), free prostate specific antigen (fPSA) and carcinoembryonic antigen (CEA) in patients with prostate cancer.</p><p><strong>Methods: </strong>Retrospective methods were used to select 120 patients with prostate cancer admitted to our hospital from January 2021 to December 2023 as prostate cancer group and 100 patients with benign hyperplasia of prostate as benign hyperplasia group. During the same period, 100 healthy subjects in physical examination center were selected as the healthy control group. Serum PSA, fPSA and CEA levels of the three groups of subjects were detected, and their differences in patients with different clinicopathological characteristics were compared. Multivariate logistic regression was used to analyze their independent risk factors.</p><p><strong>Results: </strong>The serum levels of PSA, fPSA and CEA in prostate cancer group were significantly higher than those in benign hyperplasia group, and the levels of PSA, fPSA and CEA in benign hyperplasia group were significantly higher than those in healthy control group, the difference was statistically significant (<i>P</i><0.05). Serum PSA, fPSA and CEA levels were significantly higher in patients aged ≥60 years old, Gleason score ≥7, TNM stage III+IV, high differentiated, with lymph node metastasis and bone metastasis than in patients aged < 60 years old, Gleason score < 7, TNM stage I+II, low differentiated, without lymph node metastasis or bone metastasis, the difference was statistically significant (<i>P</i><0.05). PSA≥10.05 μg/mL, fPSA≥1.50 μg/mL, CEA≥20 ng/mL were independent risk factors for poor prognosis of prostate cancer (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>Serum PSA, fPSA and CEA are significantly elevated in patients with prostate cancer, which are independent risk factors for poor prognosis and can be used as important indicators for clinicopathological evaluation and prognosis prediction.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1577-1585"},"PeriodicalIF":2.6,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Rupture of a Low-Grade Endometrial Stromal Sarcoma: A Case Report and Review of Imaging.","authors":"Jiali Jin, Yangyang Liu, Haiyan Cheng","doi":"10.2147/CMAR.S531483","DOIUrl":"10.2147/CMAR.S531483","url":null,"abstract":"<p><strong>Background: </strong>Endometrial stromal sarcoma (ESS) is a malignant tumor that develops from the mesenchymal tissue of the uterus. However, spontaneous rupture of ESS is uncommon. This case emphasizes the rarity of spontaneous rupture and the difficulties in preoperative diagnostic imaging, serving as a foundation for clinical diagnosis and prognosis.</p><p><strong>Case description: </strong>A 52-year-old woman presented at the clinic with right lower abdominal pain, persisting for over 5 days, significantly impacting her daily activities. Self-examination revealed a palpable abdominal mass. Ultrasonography identified an inhomogeneous echogenic mass within the uterus, initially suspected to be a uterine fibroid. Subsequent magnetic resonance imaging indicated uterine fibroids with tumor rupture and bleeding. The pathological assessment confirmed low-grade ESS. The patient underwent a total hysterectomy and double adnexectomy and is now 4 months postoperative and surviving well.</p><p><strong>Conclusion: </strong>This case highlights the significance of diagnosing spontaneous rupture of ESS and emphasizes the need for increased awareness and additional research on this uncommon condition. Our results enhance comprehension of spontaneous ESS rupture and underscore the critical need for further investigation into optimal treatment approaches.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1555-1561"},"PeriodicalIF":2.6,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}